值得一提的是，三叶草生物-B是首批通过港交所18A规则上市的生物科技公司之一，曾引入高瓴、淡马 锡等知名机构作为基石投资者。公司依托自主研发的Trimer-Tag平台，该技术通过模拟人体胶原蛋白三 聚体结构，可将任意病毒抗原稳定为类天然三聚体形态，已验证适用于新冠、RSV等多种疫苗开发。 三叶草生物-B(02197)盘中涨近12%，近一个月股价累计涨幅逾2倍。截至发稿，涨10%，报0.88港元， 成交额1029.42万港元。 消息面上，三叶草生物-B拟于8月26日举行董事会会议考虑及批准中期业绩。据悉，三叶草生物-B是一 家专注于呼吸道疫苗研发的生物科技公司，其核心技术平台和产品管线在行业内具有显著差异化。公司 此前宣布，一项评估SCB-1022(RSV+hMPV)及SCB1033(RSV+hMPV+PIV3)呼吸道联合疫苗候选产品的I 期临床试验已完成首批受试者入组。该等疫苗候选产品开发的融合前稳定的F(PreF)三聚体亚单位疫苗 抗原基于三叶草生物的蛋白质三聚体化疫苗技术平台。 ...

Core Viewpoint - Three Leaf Clover Biotech-B (02197) has seen a significant stock price increase, with a nearly 12% rise during trading and over a 200% increase in the past month, indicating strong market interest and potential investor confidence [1] Company Overview - Three Leaf Clover Biotech-B is a biotechnology company focused on the development of respiratory vaccines, with a differentiated core technology platform and product pipeline in the industry [1] - The company is one of the first biotech firms to list under the Hong Kong Stock Exchange's 18A rules, attracting notable institutional investors such as Hillhouse Capital and Temasek as cornerstone investors [1] Clinical Development - The company has completed the enrollment of the first batch of subjects in Phase I clinical trials for its respiratory combination vaccine candidates SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) [1] - The vaccine candidates utilize a stabilized PreF trimer subunit vaccine antigen based on the company's proprietary protein trimerization vaccine technology platform [1] Technology Platform - The Trimer-Tag™ platform developed by the company mimics the structure of human collagen trimer, allowing for the stabilization of any viral antigen into a natural trimeric form, which has been validated for the development of vaccines against various viruses, including COVID-19 and RSV [1]